secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001104659-24-089914
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports Q2 net loss of $123.1M; $16.9M cash; pipeline milestones ahead
--------------------------------------------------------------------------------

- Net loss of $123.1M ($4.87 per share) includes $117.5M non-cash charge from acquired in-process R&D.
- Cash, cash equivalents and short-term investments of $16.9M as of June 30, 2024; adequate through year-end.
- Merger with Trawsfynydd completed April 2024; concurrent $14M private placement from Orbimed and Torrey Pines.
- Tivoxavir marboxil (influenza) Phase 1 dose extension underway; topline results expected Q4 2024.
- Ratutrelvir (COVID-19) completed Phase 1 SAD/MAD; Phase 2 initiation planned Q4 2024/Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924089914/0001104659-24-089914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924089914/tm2421727d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer